CL2015000732A1 - Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica. - Google Patents

Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.

Info

Publication number
CL2015000732A1
CL2015000732A1 CL2015000732A CL2015000732A CL2015000732A1 CL 2015000732 A1 CL2015000732 A1 CL 2015000732A1 CL 2015000732 A CL2015000732 A CL 2015000732A CL 2015000732 A CL2015000732 A CL 2015000732A CL 2015000732 A1 CL2015000732 A1 CL 2015000732A1
Authority
CL
Chile
Prior art keywords
laquinimod
inhibiting
administration
pharmaceutical composition
multiple sclerosis
Prior art date
Application number
CL2015000732A
Other languages
English (en)
Spanish (es)
Inventor
Massimo Filippi
Giancarlo Comi
Maria Assunta Rocca
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CL2015000732A1 publication Critical patent/CL2015000732A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
CL2015000732A 2012-10-12 2015-03-23 Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica. CL2015000732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12

Publications (1)

Publication Number Publication Date
CL2015000732A1 true CL2015000732A1 (es) 2015-08-07

Family

ID=50475887

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000732A CL2015000732A1 (es) 2012-10-12 2015-03-23 Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
CL2016002873A CL2016002873A1 (es) 2012-10-12 2016-11-11 Composición farmacéutica para reducir el daño talámico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2016002873A CL2016002873A1 (es) 2012-10-12 2016-11-11 Composición farmacéutica para reducir el daño talámico.

Country Status (18)

Country Link
US (2) US20140107154A1 (https=)
EP (1) EP2961406A4 (https=)
JP (1) JP2015533163A (https=)
KR (1) KR20150080509A (https=)
CN (1) CN105263325A (https=)
AR (1) AR092993A1 (https=)
AU (2) AU2013329348A1 (https=)
BR (1) BR112015007782A2 (https=)
CA (1) CA2884272A1 (https=)
CL (2) CL2015000732A1 (https=)
EA (1) EA201590726A1 (https=)
HK (1) HK1218865A1 (https=)
IL (1) IL237745A0 (https=)
MX (1) MX2015004564A (https=)
PE (1) PE20151435A1 (https=)
SG (1) SG11201501874TA (https=)
TW (1) TW201420101A (https=)
WO (1) WO2014058979A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
HK1198296A1 (en) 2012-02-16 2015-03-27 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201591507A1 (ru) * 2013-02-15 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза лахинимодом
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
SG10202102198RA (en) * 2016-09-13 2021-04-29 Intekrin Therapeutics Inc Treatment of multiple sclerosis with chs-131
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
WO2008009407A2 (en) * 2006-07-17 2008-01-24 Novartis Ag Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
RS54328B1 (sr) * 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. Tretman multiple skleroze lakvinimodom
PT2467372T (pt) * 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
WO2012078591A1 (en) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
EP2691393B1 (en) * 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途

Also Published As

Publication number Publication date
KR20150080509A (ko) 2015-07-09
EP2961406A4 (en) 2017-01-04
EA201590726A1 (ru) 2015-10-30
US20160296511A1 (en) 2016-10-13
AR092993A1 (es) 2015-05-13
WO2014058979A2 (en) 2014-04-17
AU2017203896A1 (en) 2017-06-29
WO2014058979A8 (en) 2015-04-16
US20140107154A1 (en) 2014-04-17
CN105263325A (zh) 2016-01-20
WO2014058979A3 (en) 2015-08-20
PE20151435A1 (es) 2015-10-15
SG11201501874TA (en) 2015-05-28
BR112015007782A2 (pt) 2017-07-04
CL2016002873A1 (es) 2017-04-17
CN105263325A8 (zh) 2017-07-14
CA2884272A1 (en) 2014-04-17
IL237745A0 (en) 2015-05-31
AU2013329348A1 (en) 2015-05-28
JP2015533163A (ja) 2015-11-19
MX2015004564A (es) 2015-07-21
EP2961406A2 (en) 2016-01-06
HK1218865A1 (zh) 2017-03-17
TW201420101A (zh) 2014-06-01

Similar Documents

Publication Publication Date Title
CL2015000732A1 (es) Un metodo para inhibir o reducir daño talamico en un sujeto afectado por esclerosis multiple que comprende la administracion de laquinimod; composicion farmaceutica.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014003681A8 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CL2014000209A1 (es) Metodo para tratar esclerosis multiple que comprende el uso de laquinimod y acetato de glatiramero y kit que comprende composiciones farmaceuticas conteniendo a ambos compuestos independientemente.
DK3192501T3 (da) Topisk farmaceutisk sammensætning baseret på semifluorerede alkaner
BR112014003801A2 (pt) composto, composição farmacêutica, e, métodos para a inibição de romk, para a provocação de diurese, natriurese ou ambas, e para o tratamento ou a profilaxia de um ou mais distúrbios
BR112014031263A2 (pt) composto, composição farmacêutica, métodos para inibir a secreção wnt e para inibir sinalização wnt, uso do composto ou sal e método para tratar um distúrbio.
BR112013020362A2 (pt) processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
BR112014031896A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um distúrbio
BR112014026149A2 (pt) método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo.
BR112014006420A2 (pt) compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia
CL2014003503A1 (es) Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano.
BR112014031899A8 (pt) composto, composição farmacêutica, e, método para tratamento de um distúrbio
CL2013002026A1 (es) Compuesto solido (r)-1-etil-3-[5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]-urea y metodo para prepararla.
BR112014016736A2 (pt) composto, composição farmacêutica, método para tratamento, uso de um composto e invenção